(Q37741783)

22 August 2017

1 reference

title

The RAAS in the pathogenesis and treatment of diabetic nephropathy (English)

1 reference

22 August 2017

0 references

3

1 reference

22 August 2017

1

Piero Ruggenenti

1 reference

22 August 2017

2

Paolo Cravedi

1 reference

PubMed ID

20440277

22 August 2017

language of work or name

English

0 references

publication date

4 May 2010

1 reference

Nature Reviews Nephrology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

6

1 reference

22 August 2017

319-330

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2010.58

22 August 2017

0 references

cites work

Angiotensin AT1/AT2 receptors: regulation, signalling and function

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Renin, angiotensin, sodium and organ damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effect of captopril on heavy proteinuria in azotemic diabetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Renal protective effect of enalapril in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Overview of randomised trials of ACE inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Renal and retinal effects of enalapril and losartan in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Preventing microalbuminuria in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Images in clinical medicine. Paget's disease of the mandible

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Letter by Williams and Tabas regarding article "atherosclerosis 2005: recent discoveries and novel hypotheses"

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effect of ramipril on the incidence of diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Salt blocks the renal benefits of ramipril in diabetic hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Salt intake and renal outcome in patients with progressive renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Blood pressure may be sodium-dependent in diabetic patients without overt nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

The link between abdominal obesity, metabolic syndrome and cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Is there a rationale for angiotensin blockade in the management of obesity hypertension?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Supramaximal dose of candesartan in proteinuric renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Proteinuria: Increased angiotensin-receptor blocking is not the first option.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Proteinuria: Is the ONTARGET renal substudy actually off target?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Analysis of factors causing hyperkalemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Longitudinal studies on the rate of decline in renal function with age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Role of remission clinics in the longitudinal treatment of CKD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Treatment of isolated systolic hypertension in diabetes mellitus type 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

The incidence and implications of aldosterone breakthrough

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Aldosterone in clinical nephrology--old hormone, new questions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

A comparison of the aldosterone-blocking agents eplerenone and spironolactone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Predictors of hyperkalemia risk following hypertension control with aldosterone blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Aspartic proteases in drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Aliskiren combined with losartan in type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Risk:benefit assessment of old medicines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.58

Angiotensin II-mediated renal injury.

31 March 2020

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

1 reference

12 December 2020

Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group

1 reference

12 December 2020

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group

1 reference

12 December 2020

Genetics and the prediction of complications in type 1 diabetes

1 reference

12 December 2020

Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

12 December 2020

Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started

1 reference

12 December 2020

ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2010.58

1 reference

22 August 2017

1 reference

PubMed ID

20440277